The genuinely new signal is a much larger repurchase authorization. The board added 15 million shares to the existing 15 million authorization, creating capacity for up to 30 million shares; the authorization has no fixed expiration date. 〔0〕 That is meaningful capital-return flexibility, although it is an authorization rather than a commitment to buy immediately.
| Measure | Latest figure | Comparison / implication |
|---|---|---|
| Repurchase authorization | 15 million additional shares | 30 million shares authorized in total (8-K text) |
| Q2 2026 EPS | $8.05 | $4.34 in Q2 2025; $3.26 of the increase came from equity-security fair-value changes (Second-quarter 2026 highlights) |
| Q2 2026 non-GAAP operating income | $224 million | $311 million in Q2 2025 (Second-quarter 2026 highlights) |
| Q2 2026 combined ratio | 100.8% | 5.9 points worse than Q2 2025; above the company’s 92%-98% long-term target range (Second-quarter 2026 highlights) |
| YTD P&C net written premium growth | 5% | Above the company-cited 4% full-year 2026 industry projection (Performance targets & trends) |
| YTD operating cash flow | $1.356 billion | Up 29%, supporting $199 million of net investment purchases (Performance targets & trends; Income and shareholder dividends) |
The investor presentation is not a fresh earnings surprise. Most of the operating data had already been disclosed with the July 27 second-quarter release, and published trackers showed reported EPS of roughly $1.43 versus about $1.78 expected. The August 25 filing mainly repackages that quarter for investor meetings, so the new information is the buyback expansion—not a new improvement in earnings.
Underlying underwriting is the weak spot behind the polished EPS headline. The $8.05 quarterly EPS figure was heavily boosted by unrealized equity gains, while operating income fell to $224 million and the combined ratio deteriorated to 100.8%. Premium growth remains healthy, but the core insurance engine is running above breakeven for the quarter.
The buyback is supported by solid liquidity, but execution matters. Operating cash flow reached $1.356 billion year to date, up 29%, and debt-to-total-capital was only 4.6%. That makes the expanded authorization credible, but because there is no fixed expiration date and no purchase amount was announced, the immediate per-share benefit is uncertain. Net read: a modestly positive capital-allocation surprise offsets, but does not erase, the already-known underwriting pressure.
Read the original 8-K on SEC EDGAR ↗